Stereotaxis, Inc. Files Form 10-K/A Amendment No. 1: What Investors Need to Know
Stereotaxis, Inc. (NYSEAMER: STXS) has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This filing contains several important updates and disclosures that investors and shareholders should be aware of.
Key Points in the Report
- Purpose of the Amendment: The primary reason for this amendment is to include the signature and consent of the company’s independent registered public accounting firm, Ernst & Young LLP, on their audit opinion and consent. These signatures were obtained as of the date of the original 10-K filing but were inadvertently omitted in the previous submission.
- Correction of Exhibit Number: The amendment also corrects an exhibit number, which was previously filed incorrectly as Exhibit 22.1. The revised consent by Ernst & Young LLP is now properly filed as Exhibit 23.1.
- New Management Certifications: As required by Rule 12b-15 under the Securities Exchange Act of 1934, new certifications by the Principal Executive Officer (CEO) and Principal Financial Officer (CFO) are included as exhibits to this amendment.
- No Other Changes: The amendment explicitly states that, except as set forth in the amendment, it does not reflect events occurring after the date of the original 10-K filing, nor does it modify or update any other disclosures contained in the original filing other than those required to reflect the corrections above.
Details That May Affect Shareholders and Share Value
- Regulatory Compliance Restored: By amending the filing to include the omitted signatures and correcting the exhibit number, Stereotaxis is ensuring compliance with SEC regulations. This move is important to avoid any potential regulatory sanctions or questions about the validity of the company’s financial statements.
- Impact on Internal Controls and Financial Reporting: The report includes management’s certifications regarding the effectiveness of internal controls and financial reporting, which are critical for investor confidence, especially after a procedural error.
- ICFR Auditor Attestation: The amendment confirms that there is no auditor attestation required under Section 404(b) of the Sarbanes-Oxley Act, as Stereotaxis is a non-accelerated filer and a smaller reporting company.
- No Restatement for Error Correction: The amendment clarifies that there are no restatements for financial statement errors, which should reassure investors about the integrity of the company’s financial results.
- Annual Meeting Proxy Statement Incorporated by Reference: Portions of the Proxy Statement for the company’s 2026 Annual Meeting of Shareholders are incorporated by reference, covering critical items such as executive compensation, director information, and governance, which are of interest to shareholders.
Other Important Disclosures for Investors
- Company Status: Stereotaxis is not a well-known seasoned issuer, not a voluntary filer, and is currently in compliance with all reporting obligations.
- Trading Information: The company’s common stock (par value \$0.001 per share) trades under the symbol STXS on the NYSE American.
- Internal Controls: Both the CEO and CFO have certified that they have established and maintained disclosure controls and procedures and internal control over financial reporting. They have also disclosed any changes in internal controls during the last fiscal quarter that could materially affect financial reporting.
- Fraud and Deficiencies Disclosure: The management confirmed that any significant deficiencies or material weaknesses in internal controls, or any fraud involving management or employees with a significant role in internal controls, have been disclosed to the auditors and the audit committee.
Potential Price-Sensitive Implications
- Regulatory Compliance Restored: While the changes are procedural, they are highly important for maintaining regulatory compliance and investor trust. Failure to correct these omissions could have resulted in regulatory scrutiny, which might have negatively impacted the share price. By addressing these issues promptly and transparently, Stereotaxis has mitigated potential risks.
- No Adverse Financial Event: There is no change to previously reported financial results or business outlook, and no indication of internal control or reporting failures beyond the procedural error corrected by this amendment. This is a positive signal for shareholders concerned about the company’s operational integrity.
Conclusion
This amendment to the Form 10-K is primarily corrective and administrative in nature, aimed at ensuring full compliance with SEC requirements. There are no changes to the company’s financial statements, no restatements, and no new material risks disclosed. Investors should view this as a demonstration of the company’s commitment to transparency and regulatory compliance, with no negative implications for the company’s financial health or performance.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should refer to the company’s official filings with the U.S. Securities and Exchange Commission (SEC) and consult with their financial advisor before making any investment decisions. The author and publisher are not responsible for any actions taken based on this information.
